Cell Biology of Prions and Prionoids: A Status Report

Trends in Cell Biology

Volumn 26, Issue 1, 2016, Pages 40-51

  Aguzzi, Adriano ^a   Lakkaraju, Asvin K K ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Amyloid; Exosomes; Oligomers; Prionoids; Prions; Propagons; Tunneling nanotubes

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; HUNTINGTIN; NANOTUBE; OLIGOMER; PRION PROTEIN; PROTEIN AGGREGATE; TAU PROTEIN;

CELL MEMBRANE; CELL SPREADING; CENTRAL NERVOUS SYSTEM; CYTOLOGY; EXOSOME; HUMAN; INTERNALIZATION; NERVE DEGENERATION; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; PROTEOSTASIS DEFICIENCY;

AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; PRION DISEASES; PRION PROTEINS; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; PROTEOSTASIS DEFICIENCIES; TAU PROTEINS;

EID: 84955245033     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2015.08.007     Document Type: Review

References (126)

1. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
2. Aguzzi A., Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64:783-790.
3. Nelson R., et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005, 435:773-778.
4. +] prion in yeast. Genetics 2003, 165:23-33.
5. Knowles T.P., et al. An analytical solution to the kinetics of breakable filament assembly. Science 2009, 326:1533-1537.
6. Herrmann U.S., et al. Structure-based drug design identifies polythiophenes as antiprion compounds. Sci. Transl. Med. 2015, 7:299ra123.
7. Margalith I., et al. Polythiophenes inhibit prion propagation by stabilizing prion protein (PrP) aggregates. J. Biol. Chem. 2012, 287:18872-18887.
8. Newby G.A., Lindquist S. Blessings in disguise: biological benefits of prion-like mechanisms. Trends Cell Biol. 2013, 23:251-259.
9. Aguzzi A., Weissmann C. Prion research: the next frontiers. Nature 1997, 389:795-798.
10. Aguzzi A., et al. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 2007, 8:552-561.
11. Aguzzi A., et al. The immunobiology of prion diseases. Nat. Rev. Immunol. 2013, 13:888-902.
12. Aguzzi A., Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004, 116:313-327.
13. Aguzzi A. Cell biology: beyond the prion principle. Nature 2009, 459:924-925.
14. Collinge J. Human prion diseases and bovine spongiform encephalopathy (BSE). Hum. Mol. Genet. 1997, 6:1699-1705.
15. Sigurdson C.J., et al. Prion strain discrimination using luminescent conjugated polymers. Nat. Methods 2007, 4:1023-1030.
16. Lu J.X., et al. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 2013, 154:1257-1268.
17. Sanders D.W., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014, 82:1271-1288.
18. Prusiner S.B. Scrapie prions, brain amyloid, and senile dementia. Curr. Top. Cell. Regul. 1985, 26:79-95.
19. Simoneau S., et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog. 2007, 3:e125.
20. Brandner S., et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 1996, 379:339-343.
21. Cowan C.M., et al. What is the pathological significance of tau oligomers?. Biochem. Soc. Trans. 2012, 40:693-697.
22. Naslund J., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
23. LaFerla F.M., et al. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
24. Westerman M.A., et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2002, 22:1858-1867.
25. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
26. Crimins J.L., et al. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res. Rev. 2013, 12:757-763.
27. Ittner L.M., Gotz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
28. Um J.W., Strittmatter S.M. Amyloid-beta induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion 2013, 7:37-41.
29. Lauren J., et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
30. Balducci C., et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2295-2300.
31. Calella A.M., et al. Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol. Med. 2010, 2:306-314.
32. Cisse M., et al. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J. Neurosci. 2011, 31:10427-10431.
33. Kessels H.W., et al. The prion protein as a receptor for amyloid-beta. Nature 2010, 466:E3-E4. discussion E4-E5.
34. Brown P., et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. 1994, 35:513-529.
35. Eisele Y.S., et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Aβ inoculation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12926-12931.
36. Eisele Y.S., et al. Peripherally applied Aβ-containing inoculates induce cerebral beta-amyloidosis. Science 2010, 330:980-982.
37. Hamaguchi T., et al. The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain. Acta Neuropathol. 2012, 123:31-37.
38. Heilbronner G., et al. Seeded strain-like transmission of beta-amyloid morphotypes in APP transgenic mice. EMBO Rep. 2013, 14:1017-1022.
39. Tycko R., Wickner R.B. Molecular structures of amyloid and prion fibrils: consensus versus controversy. Acc. Chem. Res. 2013, 46:1487-1496.
40. Aguzzi A., Gitler A.D. A template for new drugs against Alzheimer's disease. Cell 2013, 154:1182-1184.
41. Gusella J.F., MacDonald M.E. Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem. Sci. 2006, 31:533-540.
42. Mead S., Reilly M.M. A new prion disease: relationship with central and peripheral amyloidoses. Nat. Rev. Neurol. 2015, 11:90-97.
43. Watts J.C., et al. Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:10323-10328.
44. Stohr J., et al. Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:10329-10334.
45. Aguzzi A. Neurodegeneration: Alzheimer's disease under strain. Nature 2014, 512:32-34.
46. Burre J., et al. Properties of native brain alpha-synuclein. Nature 2013, 498:E4-E6. discussion E6-E7.
47. Uversky V.N., et al. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 2001, 276:43495-43498.
48. Weinreb P.H., et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
49. Brundin P., et al. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 2008, 9:741-745.
50. Jiang P., et al. Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of alpha-synuclein oligomers and decrease of neurites. Neurobiol. Aging 2013, 34:1504-1515.
51. Conway K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:571-576.
52. Winner B., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4194-4199.
53. Luk K.C., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
54. Peelaerts W., et al. Alpha-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015, 522:340-344.
55. Ren P.H., et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 2009, 11:219-225.
56. Burke K.A., et al. Assessing mutant huntingtin fragment and polyglutamine aggregation by atomic force microscopy. Methods 2011, 53:275-284.
57. Legleiter J., et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J. Biol. Chem. 2010, 285:14777-14790.
58. Mukai H., et al. Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10887-10892.
59. Leitman J., et al. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nat. Commun. 2013, 4:2753.
60. Klement I.A., et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53.
61. Saudou F., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
62. Schaffar G., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 2004, 15:95-105.
63. Glover J.R., Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 1998, 94:73-82.
64. Kryndushkin D.S., et al. Molecular chaperone Hsp104 can promote yeast prion generation. Genetics 2011, 188:339-348.
65. Shorter J., Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 2004, 304:1793-1797.
66. Tuite M.F. Genetics. Psi no more for yeast prions. Nature 1994, 370:327-328.
67. Rampelt H., et al. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J. 2012, 31:4221-4235.
68. Winkler J., et al. Hsp70 targets Hsp100 chaperones to substrates for protein disaggregation and prion fragmentation. J. Cell Biol. 2012, 198:387-404.
69. Nillegoda N.B., et al. Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 2015, 524:247-251.
70. Stahl N., et al. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987, 51:229-240.
71. Legname G., et al. Synthetic mammalian prions. Science 2004, 305:673-676.
72. Wang F., et al. Generating a prion with bacterially expressed recombinant prion protein. Science 2010, 327:1132-1135.
73. Klohn P.C., et al. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11666-11671.
74. Falsig J., et al. A versatile prion replication assay in organotypic brain slices. Nat. Neurosci. 2008, 11:109-117.
75. Yim Y.I., et al. The multivesicular body is the major internal site of prion conversion. J. Cell Sci. 2015, 128:1434-1443.
76. Rajendran L., et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11172-11177.
77. Sharples R.A., et al. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J. 2008, 22:1469-1478.
78. Kegel K.B., et al. Polyglutamine expansion in huntingtin increases its insertion into lipid bilayers. Biochem. Biophys. Res. Commun. 2009, 387:472-475.
79. Simon D., et al. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012, 586:47-54.
80. Saman S., et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 2012, 287:3842-3849.
81. Danzer K.M., et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 2012, 7:42.
82. Mange A., et al. Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein. Biol. Cell 2004, 96:125-132.
83. Altmeppen H.C., et al. Roles of endoproteolytic alpha-cleavage and shedding of the prion protein in neurodegeneration. FEBS J. 2013, 280:4338-4347.
84. Oliveira-Martins J.B., et al. Unexpected tolerance of alpha-cleavage of the prion protein to sequence variations. PLoS ONE 2010, 5:e9107.
85. Altmeppen H.C., et al. The sheddase ADAM10 is a potent modulator of prion disease. Elife 2015, Published online February 5, 2015. 10.7554/eLife.04260.
86. Guillot-Sestier M.V., et al. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J. Biol. Chem. 2009, 284:35973-35986.
87. Bremer J., et al. Axonal prion protein is required for peripheral myelin maintenance. Nat. Neurosci. 2010, 13:310-318.
88. Marques O., Outeiro T.F. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 2012, 3:e350.
89. Menzies F.M., et al. Protein misfolding disorders and macroautophagy. Curr. Opin. Cell Biol. 2011, 23:190-197.
90. Deretic V., et al. Autophagy intersections with conventional and unconventional secretion in tissue development, remodeling and inflammation. Trends Cell Biol. 2012, 22:397-406.
91. Schotman H., et al. Integrins mediate their unconventional, mechanical-stress-induced secretion via RhoA and PINCH in Drosophila. J. Cell Sci. 2009, 122:2662-2672.
92. Giuliani F., et al. Unconventional secretion: a stress on GRASP. Curr. Opin. Cell Biol. 2011, 23:498-504.
93. Rustom A., et al. Nanotubular highways for intercellular organelle transport. Science 2004, 303:1007-1010.
94. Marzo L., et al. Multifaceted roles of tunneling nanotubes in intercellular communication. Front. Physiol. 2012, 3:72.
95. Jolly C., Sattentau Q.J. Retroviral spread by induction of virological synapses. Traffic 2004, 5:643-650.
96. Gousset K., et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 2009, 11:328-336.
97. Domert J., et al. Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol. Dis. 2014, 65:82-92.
98. Costanzo M., et al. Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J. Cell Sci. 2013, 126:3678-3685.
99. Huotari J., Helenius A. Endosome maturation. EMBO J. 2011, 30:3481-3500.
100. Sc upon prion conversion on the plasma membrane. J. Cell Sci. 2013, 126:3552-3562.
101. Sc in cell-surface, raft-associated amyloid strings and webs. J. Cell Biol. 2014, 204:423-441.
102. Goold R., et al. Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat. Commun. 2011, 2:281.
103. Omtri R.S., et al. Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery. Mol. Pharm. 2012, 9:1887-1897.
104. Poduslo J.F., et al. Alzheimer's disease amyloid beta-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils. Biochemistry 2012, 51:3993-4003.
105. Truong L.N., et al. Rapid detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors. Diagn. Pathol. 2012, 7:66.
106. Bi X., et al. Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 2002, 112:827-840.
107. 42 uptake and lysosomal trafficking. PLoS ONE 2010, 5:e11884.
108. Hu X., et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20324-20329.
109. Mishra A., et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16883-16888.
110. Guo J.L., Lee V.M. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 2011, 286:15317-15331.
111. Flach K., et al. Tau oligomers impair artificial membrane integrity and cellular viability. J. Biol. Chem. 2012, 287:43223-43233.
112. Kisos H., et al. Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies. PLoS ONE 2012, 7:e46817.
113. Konno M., et al. Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol. Neurodegener. 2012, 7:38.
114. Hansen C., et al. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
115. Angot E., et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE 2012, 7:e39465.
116. Wang W., et al. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17797-17802.
117. Lashuel H.A., et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322:1089-1102.
118. Solomon I.H., et al. Neurotoxic mutants of the prion protein induce spontaneous ionic currents in cultured cells. J. Biol. Chem. 2010, 285:26719-26726.
119. Masuda-Suzukake M., et al. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol. Commun. 2014, 2:88.
120. Pecho-Vrieseling E., et al. Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat. Neurosci. 2014, 17:1064-1072.
121. Rey N.L., et al. Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol. 2013, 126:555-573.
122. Bergermann F., et al. 2000-Fold parallelized dual-color STED fluorescence nanoscopy. Opt. Express 2015, 23:211-223.
123. Jinek M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337:816-821.
124. Grad L.I., et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:3620-3625.
125. Sonati T., et al. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature 2013, 501:102-106.
126. Willem M., et al. η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 2015, Published online August 31, 2015. 10.1038/nature14864.